Ann Surg Treat Res.  2015 Feb;88(2):106-110. 10.4174/astr.2015.88.2.106.

Transfusion free radical antegrade modular pancreaticosplenectomy of metastatic neuroendocrine tumor of the pancreas in Jehovah's Witness patient

• Jeon YB
• Yun S
• Choi D

• KMID: 1804128
• DOI: http://doi.org/10.4174/astr.2015.88.2.106

Abstract

In a popular sense, Jehovah's Witnesses (JW) have their creeds, one of which is refusal of blood transfusion. Such refusal may impinge on their proper management, especially in critical situations. We present a case of successful bloodless multimodality therapy, which was performed for a JW. The patient was a 49-year-old woman and JW who had general weakness 7 days before admission. She was diagnosed with a pancreatic neuroendocrine tumor (PNET) with hepatic metastases. Transcatheter arterial chemoembolization and Sandostatin LAR injection were performed, and then she was given a transfusion-free Radical antegrade modular pancreatosplenectomy sequentially. We gave recombinant human erythropoietin and iron hydroxide sucrose complex daily for five days after surgery. She was discharged at postoperative day 12 without any surgical complications. Multimodality therapy is very important for optimal treatment of PNET. Along with intimate interdepartmental cooperation, careful patient selection and appropriate perioperative management could possibly enhance the surgical outcome.

Keyword

Neuroendocrine tumors; Jehovah's witnesses; Pancreatectomy; Bloodless medical and surgical procedures

MeSH Terms

Blood Transfusion
Bloodless Medical and Surgical Procedures
Disulfiram
Erythropoietin
Female
Humans
Iron
Jehovah's Witnesses
Middle Aged
Neoplasm Metastasis
Neuroectodermal Tumors, Primitive
Neuroendocrine Tumors*
Octreotide
Pancreas*
Pancreatectomy
Patient Selection
Sucrose
Disulfiram
Erythropoietin
Iron
Octreotide
Sucrose

Figure

• 

  Fig. 1 Abdominal CT scan. (A, B) A huge well-capsulated tumor (indicated by the arrow) is located in pancreatic body and tail, highly enhanced by contrast material. (C-F) Multiple hepatic metastases were found in both lobes. Successful transarterial chemoembolization was done for multiple lesions in liver.

• 

  Fig. 2 Surgical dissection plan for radical antegrade modular pancreaticosplenectomy. A, left adrenal gland; C, colon; K, left kidney; P, pancreas; S, spleen.

• 

  Fig. 3 (A) Surgical field after removal of specimen showed splenic artery stump, left adrenal gland, and superior mesenteric artery (SMA). Gross specimen consists of distal pancreas with tumor mass and spleen. (B, C) On cross cut section, shows roughly ovoid white gray mass (8 cm × 6.5 cm), 1.5 cm from resection margin. Mass is composed of white gray solid creamy tissue with focal cystic change and necrosis. Mass seems to infiltrate into peripancreatic fat tissue. Several enlarged lymph nodes are found in peripancreatic fat tissue. Small clear tumor cells are spreading with trabecular configuration, and destruction of surrounding exocrine tissue show fibrosis, infiltration of mononuclear cells and disarrangement of parenchymal structure were apparent at splenic side of tumor, indicating diffuse chronic pancreatitis (D: H&E, ×10). Extensive angioinvasion is found (E: Victoria blue H&E, ×20). Tumor cells were positively stained for chromogranin A (F, ×20) and CD53 (G, ×20).

Reference

1. Chamberlain RS, Canes D, Brown KT, Saltz L, Jarnagin W, Fong Y, et al. Hepatic neuroendocrine metastases: does intervention alter outcomes? J Am Coll Surg. 2000; 190:432–445.

2. Hung JS, Chang MC, Lee PH, Tien YW. Is surgery indicated for patients with symptomatic nonfunctioning pancreatic neuroendocrine tumor and unresectable hepatic metastases? World J Surg. 2007; 31:2392–2397.

3. Magner D, Ouellette JR, Lee JR, Colquhoun S, Lo S, Nissen NN. Pancreaticoduodenectomy after neoadjuvant therapy in a Jehovah's witness with locally advanced pancreatic cancer: case report and approach to avoid transfusion. Am Surg. 2006; 72:435–437.

4. Halperin DM, Kulke MH. Management of pancreatic neuroendocrine tumors. Gastroenterol Clin North Am. 2012; 41:119–131.

5. Strasberg SM, Drebin JA, Linehan D. Radical antegrade modular pancreatosplenectomy. Surgery. 2003; 133:521–527.

6. Park HJ, You DD, Choi DW, Heo JS, Choi SH. Role of radical antegrade modular pancreatosplenectomy for adenocarcinoma of the body and tail of the pancreas. World J Surg. 2014; 38:186–193.

7. Hill JS, McPhee JT, McDade TP, Zhou Z, Sullivan ME, Whalen GF, et al. Pancreatic neuroendocrine tumors: the impact of surgical resection on survival. Cancer. 2009; 115:741–751.

8. Muniraj T, Vignesh S, Shetty S, Thiruvengadam S, Aslanian HR. Pancreatic neuroendocrine tumors. Dis Mon. 2013; 59:5–19.

9. Kondo NI, Ikeda Y, Maehara S, Sugimoto R, Nishiyama K, Sakaguchi Y. Role of resection of the primary pancreatic neuroendocrine tumor in the multidisciplinary treatment of patients with unresectable synchronous liver metastases: a case series. JOP. 2013; 14:415–422.

10. Marsh JC, Bevan DH. Haematological care of the Jehovah's Witness patient. Br J Haematol. 2002; 119:25–37.